Can combination salvage therapy for invasive aspergillosis improve patient outcome?
Raoul Herbrecht* and Shanti Natarajan-Amé
Correspondence *Department of Hematology and Oncology, Hôpital de Hautepierre, Strasbourg 67098, France
Email raoul.herbrecht@chru-strasbourg.fr
This article has no abstract so we have provided the first paragraph of the full text.
It is a well demonstrated fact that the incidence of invasive fungal infections, and especially that of invasive aspergillosis, has continued to grow over the past two decades. Many factors have contributed to this increase, including new, more intensive therapeutic strategies for cancer. Despite new tools allowing earlier and more reliable diagnosis of invasive fungal infections,1 these remain an important cause of mortality and morbidity in leukemic patients and HSCT recipients.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.